Know Cancer

forgot password

A Pharmacokinetic Study of AC480 Administered Twice Daily in Surgically Resectable Malignant Glioma Patients Not on Enzyme-Inducing Anticonvulsants

Phase 1
18 Years
Open (Enrolling)

Thank you

Trial Information

A Pharmacokinetic Study of AC480 Administered Twice Daily in Surgically Resectable Malignant Glioma Patients Not on Enzyme-Inducing Anticonvulsants

Plasma and tumoral pharmacokinetics, as well as FDG-PET data will be analyzed to determine
the intratumoral and plasma levels of AC480 obtained and its antiproliferative activity.
After recovery from surgery, all patients will resume AC480 at 300 mg orally BID until
evidence of disease progression or toxicity (Part II: Maintenance Therapy). Those patients
will be followed for determination of 6-month progression free survival. Patients will
remain on treatment for as long as they have clinical benefit from the treatment. There
will be no limit to the number of cycles of treatment a patient can receive providing they
continue to benefit from and are not intolerant to AC480 administration.

The data collected in this study will be summarized in tables listing the mean, standard
deviation, and number of patients for continuous data, or in tables listing count and
percentage for categorical data, where appropriate. All patient data will be listed by
patient or by parameter, all statistical analyses will be performed and all data appendices
will be created by using the SAS system. Pharmacokinetic analysis will be made to determine
if AC480 reaches the intracerebral tumor tissue. Comparisons will be made between the data
obtained from the plasma of the same patients treated on AC480, including determination of
the tumor-to-plasma ratio. The most common side effects of AC480 are generally mild to
moderate in severity and include: nausea, vomiting, diarrhea, fatigue, cough, elevation of
the liver enzymes, anemia, and rash.

Inclusion Criteria:

- Patients must have a histologically confirmed diagnosis of a recurrent/progressive
WHO grade 4 malignant glioma (glioblastoma multiforme or gliosarcoma) or WHO grade 3
malignant glioma (anaplastic astrocytoma, anaplastic oligodendroglioma or anaplastic
mixed glioma) and be surgical candidates. Recurrence will be defined based on the
modified MacDonald criteria or based on histopathologic confirmation of tissue
obtained via surgical intervention. Patients with prior low-grade glioma are eligible
if histologic assessment demonstrates transformation to WHO grade III or IV malignant

- Greater than or equal to 18 years old.

- Karnofsky Performance Status (KPS) greater than or equal to 60%.

- Patients must be presenting in first, second or third relapse. Relapse is defined as
progression following anti-cancer therapy other than surgery, including non-surgical
therapies that are considered standard treatment for high-grade glioma if
administered to patients with prior low-grade glioma. Prior therapy must have
included external beam radiotherapy.

- Adequate bone marrow, liver and renal function as assessed by the following:

- Hematocrit > or = to 29%

- Absolute neutrophil count (ANC) > or = to 1,500/mL

- Platelet count > or = to 125,000/mL

- Total bilirubin < or = to 1.5 x ULN

- ALT and AST < or equal to 2.5 x the ULN

- INR < 1.5 or a PT/PTT within normal limits (unless on therapeutic
anti-coagulation). Patients receiving anti-coagulation treatment with a
low-molecular weight heparin will be allowed to participate, however oral
warfarin is not permitted except for low-dose warfarin (1mg po DAILY).

- Creatinine < or = to 1.5 x ULN

- Serum Na, K+, Mg2+, Phosphate and Ca2+ Within Normal Limit (WNL)

- An interval of at least 12 weeks from completion of standard, daily XRT, unless one
of the following occurs: a) new area of enhancement on MRI imaging that is outside
the XRT field; b) biopsy proven recurrent tumor; c) radiographic evidence of
progressive tumor on 2 consecutive scans at least 4 weeks apart.

- An interval of at least 4 weeks from prior chemotherapy (except nitrosoureas which
require 6 weeks) unless there is unequivocal evidence of tumor progression and the
patient has recovered from all anticipated toxicities from prior therapy.

- An interval of a least 4 weeks from exposure to investigational agents, unless there
is unequivocal evidence of tumor progression and the patients has recovered from all
anticipated toxicities from prior therapy.

- Signed written informed consent including HIPAA language according to institutional
guidelines. This informed consent shall include language whereby Ambit shall have
access to the patient's protected health information. A signed informed consent must
be obtained prior to any study specific procedures.

- If sexually active, patients will take contraceptive measures for the duration of the
treatments and for 3 months following discontinuation of AC480.

- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
test (sensitivity < or = to 25IU HCG/L) within 72 hours prior to the start of study
drug administration. Males and females age ≥ 18 years. WOCBP include any female that
has experienced menarche and who has not undergone successful surgical sterilization
(hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not post
menopausal (defined as amenorrhea > 12 consecutive months; or women on hormone
replacement therapy [HRT] with documented serum follicle stimulating hormone [FSH]
level > 35 mIU/mL). Even women who are using oral, implanted or injectable
contraceptive hormones or mechanical products such as an intrauterine device or
barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or are
practicing abstinence or where the partner is sterile (e.g., vasectomy), should be
considered to be of childbearing potential.

- Patients having received bevacizumab are eligible four weeks after the last dose of

Exclusion Criteria:

- Subjects on enzyme-inducing antiepileptic drugs (phenytoin, phenobarbitol,
carbamazepine, oxcarbamazepine, and primidone).

- Subjects previously treated with targeted therapies to EGFR and HER2.

- More than 3 prior episodes of progressive disease.

- WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for
the entire study period and for at least 3 months after completion of the study.

- Women who are pregnant or breastfeeding.

- Men who are unwilling or unable to use an acceptable method of birth control if their
sexual partners are WOCBP for the entire study period and for at least 3 months after
completion of the study.

- A serious uncontrolled medical disorder or active infection requiring IV antibiotics,
which would impair the ability of the subject to receive protocol therapy.

- Uncontrolled or significant cardiovascular disease, including:

- A myocardial infarction within 12 months;

- Uncontrolled angina within 6 months;

- Congestive heart failure NYHA class 3 or 4, or subjects with history of
congestive heart failure NYHA class 3 or 4 in the past, unless a screening
echocardiogram (ECHO) performed within 3 months prior to study entry results in
a left ventricular ejection fraction (LVEF) that is ≥ 45%;

- Diagnosed or suspected long QT syndrome;

- Any history of clinically significant ventricular arrhythmias (such as
ventricular tachycardia, ventricular fibrillation, or torsades de pointes);

- Any subject with a history of any arrhythmia should be discussed with the Ambit
Medical Monitor prior to entry into the study;

- Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec);

- Any history of second or third degree heart block;

- Heart rate < 50 / minute on pre-entry electrocardiogram;

- Uncontrolled hypertension.

- Human immunodeficiency virus (HIV) positivity.

- Active hepatitis (hep) B or C or other active liver disease.

- Persistent clinically significant toxicity from prior chemotherapy that is Grade 2 or
higher by the National Cancer Institute Common Terminology Criteria for Adverse
Events (CTCAE v3) (see Inclusion Criteria).

- Drugs (or medical conditions) that are generally accepted to have a risk of causing
torsades de pointes (see Appendix E). Subjects who have discontinued any of these
medications must have a wash-out period of at least 5 days or 5 half-lives of the
drug (whichever is greater) prior to the first dose of AC480.

- Proton pump inhibitors and histamine H2 antagonists. Other antacid agents may be
taken, but not within 8 hours before or 4 hours after dosing of AC480. A detailed log
recording administration of other antacids in relation to AC480 must be kept.

- Medical condition, serious intercurrent illness, or other extenuating circumstance
that, in the judgment of the Principal Investigator, could jeopardize subject safety
or interfere with the objectives of the study.

- Patient is < 3 years free of another primary malignancy except: if the other primary
malignancy is not currently clinically significant or requiring active intervention,
or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in

- Concurrent administration of warfarin, rifampin or St. John's Wort, except for
low-dose warfarin (1mg po DAILY).

- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
treatment of either a psychiatric or physical (e.g., infectious) illness.

Type of Study:


Study Design:

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Intratumoral and plasma pharmacokinetics of AC480 will be obtained on surgical tissue specimens from 5 patients treated pre-operatively with AC480.

Outcome Time Frame:

At time of resection

Safety Issue:


Principal Investigator

Annick Desjardins, MD, FRCPC

Investigator Role:

Principal Investigator

Investigator Affiliation:

Duke University Health System


United States: Food and Drug Administration

Study ID:




Start Date:

November 2009

Completion Date:

March 2013

Related Keywords:

  • Glioma
  • malignant glioma
  • glioblastoma multiforme
  • gliosarcoma
  • anaplastic astrocytoma
  • anaplastic oligodendroglioma
  • anaplastic mixed glioma
  • Pro00018751
  • Duke
  • Ambit
  • AC480
  • Glioma



The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center Durham, North Carolina  27710